◎ Sugi Atlas

Atlas / Drug / Atorvastatin

Atorvastatin

drug
On this page

Also known as AtorvastatinaAtorvastatineCardylLipitorPrevencorSortisTahorZaratorATORVASTATIN CALCIUMSID29215408Atorvastatin acidAtrovastatinSID124892211SID99355609SID144212734

Summary

Atorvastatin (CHEMBL1487) is an approved small molecule (ATC C10AA05) targeting HMGCR; indicated across 108 conditions including cardiovascular disorder and metabolic syndrome x.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: C10AA05
  • Targets: 1 (HMGCR)
  • Indications: 108 conditions
  • Clinical trials: 784
  • Chemistry: 558.6 Da · C33H35FN2O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1487
NameAtorvastatin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID60823
ChEBICHEBI:39548
ATCC10AA05
Molecular formulaC33H35FN2O5
Molecular weight558.6
InChIKeyXUKUURHRXDUEBC-KAYWLYCHSA-N

SMILES: CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4

IUPAC name: (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid

ChEBI definition: A dihydroxy monocarboxylic acid that is a member of the drug class known as statins, used primarily for lowering blood cholesterol and for preventing cardiovascular diseases.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Atorvastatin, Atorvastatina, Atorvastatine, Cardyl, Lipitor, Prevencor, Sortis, Tahor, Zarator, ATORVASTATIN, LIPITOR, ATORVASTATIN CALCIUM

Parent form; salt/anhydrous children: CHEMBL393220, CHEMBL3349878

Patent coverage: 18,407 distinct patent families (68,788 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
HMGCRhydroxymethylglutaryl-CoA reductaseCompetitive7.8584.4%P04035

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, Protein deacetylase HDAC6, Histone deacetylase 2, Thyroid hormone receptor beta, Bile acid receptor, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, Histone deacetylase 1, Cytochrome P450 3A4, Nuclear receptor subfamily 1 group I member 2, Cruzipain.

Bioactivity

ChEMBL activities: 19 potent at pChembl ≥ 5 of 30 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
HMGCR9.64IC500.23nMCHEMBL_ACT_7606224
P516398.42IC503.8nMCHEMBL_ACT_2075559
HMGCR8.22IC506nMCHEMBL_ACT_1439884
HMGCR8.21Ki6.2nMCHEMBL_ACT_18916437
P516398.21IC506.2nMCHEMBL_ACT_2218036
P516398.15IC507nMCHEMBL_ACT_17678556
HMGCR7.94IC5011.6nMCHEMBL_ACT_17773211
P516397.92IC5012nMCHEMBL_ACT_2064391
HMGCR7.89IC5012.9nMCHEMBL_ACT_12718209
SLCO1B16.22IC50600nMCHEMBL_ACT_15448316
SLCO1B16.1IC50800nMCHEMBL_ACT_15448325
SLCO1B16.06IC50870nMCHEMBL_ACT_11000887
Q1W6756.03IC50930nMCHEMBL_ACT_18474230
SLCO1B15.8IC501600nMCHEMBL_ACT_15448331
ABCG25.37IC504300nMCHEMBL_ACT_24777401
RHOC5.3IC505000nMCHEMBL_ACT_25481071
CYP3A45.29IC505100nMCHEMBL_ACT_5234095
NR1H45.17AC506800nMCHEMBL_ACT_25234601
P257795.15Potency7080nMCHEMBL_ACT_4005399

Target pathways

Aggregated over 1 target gene(s): HMGCR.

Top Reactome pathways

5 total, by targets touching each:

PathwayTargetsGenes
Cholesterol biosynthesis1HMGCR
PPARA activates gene expression1HMGCR
Activation of gene expression by SREBF (SREBP)1HMGCR
EGR2 and SOX10-mediated initiation of Schwann cell myelination1HMGCR
Lanosterol biosynthesis1HMGCR

Dominant GO biological processes

GO termTargets
cholesterol biosynthetic process1
isoprenoid biosynthetic process1
visual learning1
coenzyme A metabolic process1
sterol biosynthetic process1
negative regulation of protein catabolic process1
negative regulation of protein secretion1
long-term synaptic potentiation1
regulation of ERK1 and ERK2 cascade1
negative regulation of amyloid-beta clearance1
lipid metabolic process1
steroid biosynthetic process1
steroid metabolic process1
cholesterol metabolic process1

Indications & clinical

Indications

108 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
cardiovascular disorder4MONDO:0004995EFO:0000319
metabolic syndrome X3MONDO:0011565EFO:0000195
atherosclerosis3MONDO:0005311EFO:0003914
familial hypercholesterolemia3MONDO:0005439EFO:0004911
breast neoplasm3MONDO:0021100MONDO:0007254
diabetes mellitus3MONDO:0005015EFO:0000400
hypertriglyceridemia3MONDO:0005347EFO:0004211
type 2 diabetes mellitus3MONDO:0005148MONDO:0005148
hyperlipidemia3MONDO:0021187MONDO:0021187
HIV infectious disease3MONDO:0005109EFO:0000180
metastatic prostate carcinoma3MONDO:0004956EFO:0000196
atrial fibrillation3MONDO:0004981EFO:0000275
hypertensive disorder3MONDO:0005044EFO:0000537
hypertrophic cardiomyopathy3MONDO:0005045EFO:0000538
preeclampsia3MONDO:0005081EFO:0000668
prostate adenocarcinoma3MONDO:0005082EFO:0000673
psoriasis3MONDO:0005083EFO:0000676
coronary artery disorder3MONDO:0005010EFO:0001645
kidney disorder3MONDO:0005240EFO:0003086
chronic kidney disease3MONDO:0005300EFO:0003884
acute coronary syndrome3MONDO:0005542EFO:0005672
acute chest syndrome3MONDO:0005632EFO:0007129
ST-elevation myocardial infarction3MONDO:0041656EFO:0008585
kidney failure3MONDO:0001106HP:0000083
Alzheimer disease3MONDO:0004975MONDO:0004975
systemic lupus erythematosus3MONDO:0007915MONDO:0007915
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
periodontitis2MONDO:0005076EFO:0000649
hepatitis C virus infection2MONDO:0005231EFO:0003047
paraplegia2MONDO:0003757HP:0001258
cardiomyopathy2MONDO:0004994EFO:0000318
Crohn disease2MONDO:0005011EFO:0000384
cutaneous melanoma2MONDO:0005012EFO:0000389
glioblastoma2MONDO:0018177EFO:0000519
leukemia2MONDO:0005059EFO:0000565
lymphoma2MONDO:0005062EFO:0000574
myocardial infarction2MONDO:0005068EFO:0000612
neoplasm2MONDO:0005070EFO:0000616
renal cell carcinoma2MONDO:0005086EFO:0000681
rheumatoid arthritis2MONDO:0008383EFO:0000685
stroke disorder2MONDO:0005098EFO:0000712
pulmonary arterial hypertension2MONDO:0015924EFO:0001361
age-related macular degeneration2MONDO:0005150EFO:0001365
cirrhosis of liver2MONDO:0005155EFO:0001422
metabolic dysfunction-associated steatotic liver disease2MONDO:0013209EFO:0003095
heart failure2MONDO:0005252EFO:0003144
inflammatory bowel disease2MONDO:0005265EFO:0003767
brain aneurysm2MONDO:0005291EFO:0003870
obstructive sleep apnea syndrome2MONDO:0007147EFO:0003918
relapsing-remitting multiple sclerosis2MONDO:0005314EFO:0003929
vitiligo2MONDO:0008661EFO:0004208
focal segmental glomerulosclerosis2MONDO:0100313EFO:0004236
nephrotic syndrome2MONDO:0005377EFO:0004255
vascular disorder2MONDO:0005385EFO:0004264
osteoarthritis, knee2MONDO:0005416EFO:0004616
non-Hodgkin lymphoma2MONDO:0018908EFO:0005952
autoimmune thrombocytopenic purpura2MONDO:0008558EFO:0007160
influenza2MONDO:0005812EFO:0007328
carotid artery disorder2MONDO:0005269EFO:0009783
inflammatory breast carcinoma2MONDO:0006804EFO:1000984
metabolic dysfunction-associated steatohepatitis2MONDO:0007027EFO:1001249
scleroderma2MONDO:0019340EFO:1001993
Chagas disease2MONDO:0001444MONDO:0001444
depressive disorder2MONDO:0002050MONDO:0002050
kidney cancer2MONDO:0002367MONDO:0002367
acute kidney injury2MONDO:0002492MONDO:0002492
diabetes insipidus2MONDO:0004782MONDO:0004782
asthma2MONDO:0004979MONDO:0004979
type 1 diabetes mellitus2MONDO:0005147MONDO:0005147
migraine disorder2MONDO:0005277MONDO:0005277
multiple sclerosis2MONDO:0005301MONDO:0005301
sickle cell disease2MONDO:0011382MONDO:0011382
nasopharyngeal carcinoma2MONDO:0015459MONDO:0015459
tuberculosis2MONDO:0018076MONDO:0018076
osteonecrosis2MONDO:0005380MONDO:0018373
sarcoidosis2MONDO:0019338MONDO:0019338
Ebola hemorrhagic fever1MONDO:0005737EFO:0007243
myelodysplastic syndrome1MONDO:0018881EFO:0000198
acute myeloid leukemia1MONDO:0018874EFO:0000222
colorectal adenocarcinoma1MONDO:0005008EFO:0000365
epilepsy1MONDO:0005027EFO:0000474
obesity disorder1MONDO:0011122EFO:0001073
plasma cell myeloma1MONDO:0009693EFO:0001378
Kawasaki disease1MONDO:0012727EFO:0004246
sleep disorder1MONDO:0100081EFO:0008568
essential hypertension1MONDO:0001134MONDO:0001134
venous thromboembolism0MONDO:0005399EFO:0004286
endometrium neoplasm0MONDO:0021251MONDO:0011962

20 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 784.

Phase distribution

PhaseTrials
PHASE4214
PHASE3168
PHASE2143
PHASE1116
Not specified101
PHASE2/PHASE320
PHASE1/PHASE213
EARLY_PHASE19

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02099123PHASE4ACTIVE_NOT_RECRUITINGA Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)
NCT03024684PHASE4ACTIVE_NOT_RECRUITINGStatin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment
NCT03753555PHASE4RECRUITINGThe Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques
NCT04347434PHASE4RECRUITINGAssessment of the Effects of Long-term Lipid-lowering Therapy in Patients With Primary STEMI or NSTEMI
NCT05030818PHASE4RECRUITINGCross-over Study of Coronary Risk Factors With a Polypill
NCT05589454PHASE4NOT_YET_RECRUITINGIntracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds
NCT05641753PHASE4RECRUITINGCholesterol Lowering and Residual Risk in Diabetes, Type 1
NCT05912686PHASE4NOT_YET_RECRUITINGHigh-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients
NCT06308952PHASE4RECRUITINGAtorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation
NCT06372925PHASE4RECRUITINGIntravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT06632379PHASE4RECRUITINGAtorvaStatin Postpartum and Reduction of Cardiovascular risK
NCT06750783PHASE4RECRUITINGThe Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes
NCT06765265PHASE4RECRUITINGImpact of Atorvastatin Versus Rosuvastatin on 25 Hydroxy Vitamin D Levels in Patients With Acute Coronary Syndrome
NCT06784557PHASE4RECRUITINGEffect of Ezetimibe on Gut Microbiota
NCT06785974PHASE4NOT_YET_RECRUITINGStatins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis
NCT06789432PHASE4RECRUITINGEfficacy and Safety of Atorvastatin and Ezetimibe (10/10mg) Fixed Dose Combination Versus Atorvastatin (20mg) Monotherapy in Bangladeshi Population
NCT06856772PHASE4NOT_YET_RECRUITINGRandomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial
NCT07042165PHASE4RECRUITINGTreatment of Bile Acid Diarrhoea With Atorvastatin
NCT07462715PHASE4NOT_YET_RECRUITINGStatins Against Bushfire Smoke
NCT00079638PHASE4COMPLETEDComparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
NCT00120055PHASE4COMPLETEDAssociation Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
NCT00120887PHASE4COMPLETEDLupus Atherosclerosis Prevention Study
NCT00124397PHASE4COMPLETEDAtorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00141141PHASE4COMPLETEDEfficacy And Safety Study Of Atorvastatin Versus Simvastatin In Type 2 Diabetic Subjects With Hypercholesterolemia
NCT00141232PHASE4COMPLETEDEvaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT00147602PHASE4COMPLETEDLipitor In The Prevention Of Stroke, For Patients Who Have Had A Previous Stroke
NCT00150384PHASE4COMPLETEDClinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population
NCT00157924PHASE4COMPLETEDEzetimibe (+) Simvastatin vs. Atorvastatin Comparative Study in DM or Metabolic Syndrome Patients (0653A-093)
NCT00159718PHASE4COMPLETEDDouble Blind Atorvastatin Amlodipine Study
NCT00159835PHASE4COMPLETEDAtorvastatin Versus Simvastatin In The Prevention Of Coronary Heart Disease (CHD) In Patients With Known CHD
NCT00163150PHASE4COMPLETEDVasomotor Reactivity In Cerebral Small Vessel Disease And New Approach To Treat Lacunar Stroke
NCT00163202PHASE4COMPLETEDComparative Atorvastatin Pleiotropic Effects
NCT00166504PHASE4COMPLETEDEzetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED)
NCT00166530PHASE4COMPLETEDEASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)
NCT00174330PHASE4COMPLETEDComparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And Dyslipidemia
NCT00181181PHASE4TERMINATEDThe Effect of Statin Use on Vascular Function in Hypertensive Subjects
NCT00194402PHASE4COMPLETEDSLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
NCT00199745PHASE4COMPLETEDDifferences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity
NCT00211939PHASE4COMPLETEDCARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients
NCT00233480PHASE4COMPLETEDStatin Therapy in Heart Failure: Potential Mechanisms of Benefit

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (4) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

GuidelineSourceGene(s)DosingRecommendation
Annotation of DPWG Guideline for atorvastatin and SLCO1B1DPWGSLCO1B1yesyes
Annotation of CPIC Guideline for atorvastatin and SLCO1B1CPICSLCO1B1yesyes
Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatinCPICABCG2
Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatinCPICCYP3A4;CYP3A5;HMGCR

PharmGKB also curates 54 clinical and 296 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

13 molecules share ≥1 primary target. Top 13 by shared-target count:

MoleculeSourceStatusShared targets
LOVASTATINChEMBL + PubChemPhase 4 (approved)HMGCR
PITAVASTATINChEMBL + PubChemPhase 4 (approved)HMGCR
PRAVASTATINChEMBL + PubChemPhase 4 (approved)HMGCR
ROSUVASTATINChEMBL + PubChemPhase 4 (approved)HMGCR
SIMVASTATINChEMBL + PubChemPhase 4 (approved)HMGCR
CERIVASTATINChEMBLPhase 4 (approved)HMGCR
CISAPRIDEChEMBLPhase 4 (approved)HMGCR
FLUVASTATINChEMBLPhase 4 (approved)HMGCR
TANNIC ACIDChEMBLPhase 4 (approved)HMGCR
GLENVASTATINChEMBLPhase 2HMGCR
MEGLUTOLChEMBLPhase 2HMGCR
MEVASTATINChEMBLPhase 2HMGCR
VorinostatPubChemApprovedHMGCR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot